secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001645113-23-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint
--------------------------------------------------------------------------------

- Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.
- LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).
- Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.
- Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.
- PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/nvcr-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer